Yvonne Chang, PhD
About Yvonne Chang, PhD
Yvonne Chang, PhD, is a Scientist specializing in Toxicology at Bristol Myers Squibb in Brisbane, California. She has a diverse background in toxicology research and education, with experience at MyoKardia, Reynolds American Inc., and Oregon State University.
Company
Yvonne Chang, PhD, is currently employed at Bristol Myers Squibb as a Scientist specializing in Toxicology. Her work is based in Brisbane, California, United States. Bristol Myers Squibb is a leading biopharmaceutical company that focuses on developing innovative medicines for patients with serious diseases.
Title
Yvonne Chang holds the title of Scientist with a specialization in Toxicology. Her role involves conducting research and evaluating the safety of various chemical substances to ensure the health and safety of patients.
Education and Expertise
Yvonne Chang completed her Doctor of Philosophy (PhD) in Toxicology at Oregon State University, with a focus on computational toxicology and risk assessment, spanning from 2015 to 2020. Prior to that, she earned a Bachelor of Science (B.S.) in Toxicology from the University of California, Davis, from 2011 to 2015. Her expertise includes computational toxicology, risk assessment, and chemical safety evaluation.
Professional Background
Before joining Bristol Myers Squibb, Yvonne Chang built a robust professional background in various roles. She was a Scientist I in Toxicology and Pathology at MyoKardia for 7 months from 2020 to 2021 in Brisbane, CA. She also interned in Scientific and Regulatory Affairs focusing on Product Stewardship at Reynolds American Inc. for 2 months in 2019 in Winston Salem, North Carolina. Additionally, she served as a Visiting Scholar at the University of North Carolina at Chapel Hill for 1 month in 2019.
Achievements
Yvonne Chang has several notable achievements, including publishing a research paper on computational toxicology during her PhD at Oregon State University. She presented her findings at the Society of Toxicology Annual Meeting in 2019 and received the Best Poster Award at the Pacific Northwest Society of Environmental Toxicology and Chemistry (PNW-SETAC) conference in 2018. Moreover, she developed a new risk assessment model for evaluating chemical safety during her tenure at MyoKardia.